Boston-based, biotech-focused venture capital firm Third Rock Ventures has raised $1.1 billion for its new Fund VI. Third Rock employs a hands-on approach to partnering with founders to build companies and provides early and rigorous integration of science, medicine, business and strategy to build successful companies. To date, Third Rock has raised $3.8 billion and […]

Takeda has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of R&D and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories featuring modern design elements and upgraded […]

Bayer AG has opened its new Research and Innovation Center at Kendall Square, expanding further the company’s footprint into one of the world’s most innovative pharmaceutical R&D hubs. Representing a total $140M investment into the area, Bayer’s 62,100-square-foot building houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for […]

In April Boston-based Ginkgo Bioworks announced plans to significantly expand its platform capabilities in agricultural biologicals through a partnership with German conglomerate Bayer AG in which Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics R&D site, team, and internal discovery and lead optimization platform. In addition, Ginkgo will integrate the R&D platform assets from Joyn […]

Flagship Pioneering has unveiled ProFound Therapeutics, a company founded at Flagship Labs in 2020. The company’s ProFoundry Platform has uncovered tens of thousands of novel proteins, remapping the landscape of the human genome and vastly expanding the number of potential therapeutic targets. Flagship has initially committed $75M to advance the platform and generate an initial […]

Local biotechs continue to attract funding. Boston startup MOMA Therapeutics recently completed a $150 million Series B financing. “Since our launch in 2020, MOMA has advanced our novel drug discovery platform, generated multiple high-impact oncology programs and bolstered our exceptional team. Through these achievements we are developing an explicit understanding of the dynamic conformational changes of molecular […]